Correlating TCR diversity to immune reconstitution after cord blood transplant

Information

  • Research Project
  • 8199243
  • ApplicationId
    8199243
  • Core Project Number
    R43HL106868
  • Full Project Number
    1R43HL106868-01A1
  • Serial Number
    106868
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    8/1/2011 - 13 years ago
  • Project End Date
    1/31/2012 - 12 years ago
  • Program Officer Name
    MITCHELL, PHYLLIS
  • Budget Start Date
    8/1/2011 - 13 years ago
  • Budget End Date
    1/31/2012 - 12 years ago
  • Fiscal Year
    2011
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/29/2011 - 13 years ago

Correlating TCR diversity to immune reconstitution after cord blood transplant

DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a method to objectively measure immune reconstitution following hematopoietic stem cell transplantation using direct sequencing of the T-cell repertoire. This method will be developed using data from patients treated with stem cells derived from umbilical cord blood. Umbilical cord blood (CB) has emerged as an effective source of stem cells and has several advantages over conventional stem cell sources. However, cord blood recipients are at significant risk of delayed hematopoietic recovery and immune reconstitution, and thus appear to have higher susceptibility to infections, particularly from viral pathogens. The high rate of infections is associated with an alarming level of morbidity and mortality. At present, there is no objective measurement available for clinicians to determine the extent of immune reconstitution in transplant patients, and there are risks and side-effects associated with treatments currently used to prevent infections. The ability to measure immune reconstitution will relieve clinicians and their patients of the burdens associated with excessive, or insufficient, prophylactic treatments. Herein, we propose to utilize our high-throughput TCR sequencing assay to quantify the T-cell repertoire over time in individuals who have undergone cord blood transplantation. We will establish the correlation between the T-cell repertoire and reconstitution of clinical immunity. The ability to simultaneously sequence millions of individual T-cell receptor genes in single individuals provides, for the first time, the potential to directly observe changes in the immune repertoire, and this could allow clinicians to make better informed decisions about patient care. PUBLIC HEALTH RELEVANCE: The goal of this Phase I project is to develop a method to objectively measure immune reconstitution following hematopoietic stem cell transplantation using direct sequencing of the T cell repertoire. This method will be developed using umbilical cord blood transplant data, but will be relevant and beneficial to the broader transplantation field.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    148999
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:148999\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ADAPTIVE BIOTECHNOLOGIES CORPORATION
  • Organization Department
  • Organization DUNS
    832591544
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981027402
  • Organization District
    UNITED STATES